ClinicalTrials.gg
CompletedNCT03346486BRAVEUpdated Jun 20, 2018

Dietary Intervention With Brain-friendly Diet

An interventional study of Control diet and Intervention diet in Physiological Stress, Cognitive Performance and LDL Cholesterol, sponsored by Fazer Group. Completed at 1 site in Finland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-20.

Sponsored by Fazer Group · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the effect of dietary intervention on metabolic risk profile, and on potential simultaneous changes in physiological and cognitive functions and to collect a unique database using state-of-the-art technologies on variables related to the above mentioned areas.

Read the detailed description

The study is compiled from 4 phases: 1) a pilot study to evaluate performance and feasibility of the measurements and logistics for the BRAVE intervention study (N=10), 2) a pre-screening phase to select volunteers for the intervention study based on metabolite analyses (N=600), 3) the BRAVE intervention study as a controlled non-randomized open-label fixed sequence diet switch trial (N=88)and 4) a non-interventional reference group to estimate the learning effect due to repeated cognitive testing (N=30).

The Brainfood dietary regime is planned optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work -according to the so-called plate model and optimized recipes- will be provided.

02

Conditions studied

  • Physiological Stress
  • Cognitive Performance
  • LDL Cholesterol

Browse trials for

Keywords

  • Diet
  • Metabolites
  • Cognitive function
  • Physiology
  • LDL
  • Diet Habit
  • Diet Modification
03

In context

Feeding Behavior

985 studies on the registry are indexed under Feeding Behavior; 178 are open to participants now.

This study's enrollment of 88 is above the median of 77 across 700 interventional studies indexed under Feeding Behavior.

Browse Feeding Behavior studies →

Lead sponsor

This is the only study on the registry with Fazer Group as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written
  2. Age 18-65 years
  3. Assumed metabolic risk based on pre-screening assessment of glucose and lipid metabolism related metabolites defined initially as being within the most impaired quartile with reference to available metabolite data-base from a comparable population. If recruitment efficiency requires, having a metabolic profile within the most impaired half instead of a quartile may be applied.
  4. Male or female with at least 1/3 of the gender defined predominant among screened participants with assumed metabolic risk
  5. Adequate Finnish or English skill to comprehend trial related instructions and questionnaires
  6. Chest circumference of 75 to 115 cm (limits included)

Exclusion criteria

Exclusion criteria

  1. High probability to travel for more than one working day a week during the trial
  2. Expected or planned major changes in lifestyle (diet, level of exercise, significant changes in work) or involved in the R\&D of the measuring devices applied in the trial
  3. Allergies restricting compliance with control or intervention diet (celiac disease, gluten free diet, stringent FODMAP diet)
  4. Nickel allergy
  5. History of unstable coronary artery disease (myocardial infarction, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), temporal ischemic attack within the previous 6 months
  6. Diagnosed type 1 or type 2 diabetes requiring treatment
  7. Inflammatory bowel disease or other intestinal or oesophageal disease requiring medical treatment or likely to have a nutritional affect
  8. History of malignant diseases like cancer within five years prior to recruitment
  9. Lipid lowering medication (statin, cholestyramine) or medication for obesity (orlistat, or liraglutide) or depression
  10. Alcohol abuse (> 4 portion/per day) or recreational drug abuse
  11. Pregnancy or planned pregnancy or lactating
  12. Suspected low compliance according to the investigator's assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Placebo comparator
    Control diet

    Regular diet

    Other: Control diet

  • Active comparator
    Intervention diet

    Brainfood diet

    Other: Intervention diet

Interventions

  • OtherControl diet

    Regular diet

  • OtherIntervention diet

    Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.

    Also known as: Brainfood diet

06

What researchers measure

Primary outcomes

  1. Change in LDL cholesterol

    Change in serum LDL concentration between control period and intervention period

    Time frame: 8 weeks

Secondary outcomes

  1. Change in serum metabolite concentrations

    Change in serum metabolite concentrations

    Time frame: 8 weeks

  2. Change in cognitive performance

    Change in cognitive performance

    Time frame: 4 weeks

  3. Changes in self-reported vigilance

    Changes in self-reported vigilance

    Time frame: 4 weeks

  4. Changes in self-reported task load

    Changes in self-reported task load

    Time frame: 4 weeks

  5. Daily pulse profile (evening- night- morning)

    Changes in pulse profile (evening- night- morning), mean level, between control period and intervention period

    Time frame: 8 weeks

  6. Daily profile of heart rate variability (evening- night- morning)

    Changes in heart rate variability profile (evening- night- morning), between control period and intervention period

    Time frame: 8 weeks

  7. Change in dietary habits and nutrient intake

    Change in dietary habits and nutrient intake according to a standard 3-day food record between control period and intervention period

    Time frame: 8 weeks

  8. Number of adverse events

    Number of adverse events

    Time frame: 8 weeks

07

Study locations

1 site
  • Medfiles BRAVE clinic
    Espoo, Finland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Apr 2018, 7 months.

Of 515 interventional studies with no phase under Feeding Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2017
First posted
Nov 17, 2017
StartActual
Aug 24, 2017
Primary completionActual
Apr 3, 2018
CompletionActual
Apr 3, 2018
Last update
Jun 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03346486
Lead sponsor
Fazer Group
Collaborators
Nokia Technologies Oy, Nightingale Health Oy, Tekes - the Finnish Funding Agency for Innovation, Finnish Institute of Occupational Health (FIOH), Oy Medfiles Ltd
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Aug 24, 2017
Primary completion
Apr 3, 2018
Completion
Apr 3, 2018
Last update
Jun 20, 2018

Study contacts

Arja Uusitalo, MD
principal investigator · FIOH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion